Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Stockholders Equity of $139.07 million for the year ending 2025.
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +540.0% in Stockholders Equity from 2024 to 2025.
- This data is from RHYTHM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$51.86 million | Q1 2018: $133.66 million | Q2 2018: $284.32 million | Q3 2018: $269.64 million | Q1 2019: $220.49 million | Q2 2019: $181.47 million | Q3 2019: $149.12 million | Q1 2020: $253.10 million | Q2 2020: $225.75 million | Q3 2020: $196.94 million | Q1 2021: $380.95 million | Q2 2021: $351.69 million | Q3 2021: $322.26 million | Q1 2022: $235.77 million | Q2 2022: $195.63 million | Q3 2022: $281.20 million | Q1 2023: $219.76 million | Q2 2023: $182.29 million | Q3 2023: $197.47 million | Q1 2024: $61.58 million | Q2 2024: $39.34 million | Q3 2024: $11.22 million | Q1 2025: $18.95 million | Q2 2025: -$11.91 million | Q3 2025: $148.82 million.
- Over the full 12 years of available data (2014 to 2025), RHYTHM PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 38,946.1%.
- Historical annual values: Fiscal year 2025: $139.07 million | Fiscal year 2024: $21.73 million | Fiscal year 2023: $169.76 million | Fiscal year 2022: $264.26 million | Fiscal year 2021: $284.15 million | Fiscal year 2020: $166.53 million | Fiscal year 2019: $281.02 million | Fiscal year 2018: $246.26 million | Fiscal year 2017: $144.79 million | Fiscal year 2016: -$32.70 million | Fiscal year 2015: -$8.00 million | Fiscal year 2014: -$358.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: